What I think will happen to the AstraZeneca share price

The AstraZeneca plc (LON: AZN) share price has been going up and up, and here’s what I think will happen next.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Q1 results from AstraZeneca (LSE: AZN) showed just why the share price has been rising. Product sales grew by 14% year-on-year, with new medicines growing by an impressive 83%. This bodes well for the company as it relies on new drugs to outweigh the loss of patents on some of its older ‘blockbuster’ drugs (meaning those medicines with sales of over £1bn a year). The same set of results also showed total revenue was up by 11% and core operating profit up 96%.

The opportunity

For AstraZeneca, the two exciting avenues for growth come from emerging markets and new medicines. Growth in emerging markets has been strong. In Q1, sales in these territories grew by 22%, with China doing particularly well as it rose 28%. Overall, emerging markets account for 37% of product sales and this is on an upward trajectory as Q1 emerging markets sales totalled $2bn.

One of the pharma company’s most exciting new drugs, lung cancer treatment Tagrisso, is doing particularly well in emerging markets, again an example of just how important these countries are, with sales up by a massive 108%. That was far higher than the (admittedly-still-impressive) 55% growth in Europe for the same drug.

New drugs are the lifeblood of any pharma group and are especially so when patents are running out. When it comes to replacing these drugs, AstraZeneca seems to be on the right track. Investment in R&D over recent years looks to be feeding into some potentially massive oncology and respiratory medicines which could become patent-protected blockbusters that will underpin shareholder returns for years.

Reflecting the opportunity, AstraZeneca’s shares have been on the charge, pushing up the P/E to around 23. The group does offer an above inflation yield of a little more than 3%, which has dropped because of the good run for the share price, so I will be looking to take advantage of any dips, although they might be few and far between. H1 2019 results on 25 July will offer more updates on the progress of the drug pipeline and sales in emerging markets and I expect further good news to keep pushing the share price higher.

A broad church

Rival pharma group GlaxoSmithKline (LSE: GSK) is a little less reliant on new drugs as it still has a consumer arm. But under CEO Emma Walmsley, appointed in 2017, it’s focusing heavily on developing new drugs.

The group has been reshuffling its consumer arm significantly over the last three years – the Horlicks brand has been sold, and a deal with Pfizer was announced at the end of 2018 for a joint venture comprising both their consumer health businesses. It is expected that the consumer division will be spun off within a few years, making GSK more focused on developing prescription drugs and vaccines.

Like AstraZeneca, GSK has been investing heavily in oncology. This includes the $5.1bn acquisition of Tesaro and a tie up with Merck that could set Glaxo back €3.7bn. The success of its pipeline will also be critical to its future success.

GlaxoSmithKline has a lot more divisions to manage and this – alongside lower growth – I think explains why its share price is not doing as well as AZN’s. The upside for investors seeking more value is that the shares have a P/E of 13 and a yield of 5%, making it an affordable pick for long-term growth.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Andy Ross has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »